Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
AstraZeneca
Merck
Express Scripts
Moodys

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,366,600

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,366,600 protect, and when does it expire?

Patent 8,366,600 protects ZECUITY and is included in one NDA.

This patent has twenty patent family members in twelve countries.

Summary for Patent: 8,366,600
Title:Polyamine enhanced formulations for triptan compound iontophoresis
Abstract: A patch and compositions for iontophoresis of triptan compounds are described.
Inventor(s): Sebree; Terri B. (Gladwyne, PA), Horstmann; Michael (Neuwied, DE), Sameti; Mohammad (Bonn, DE)
Assignee: NuPathe Inc. (Conshohocken, PA)
Application Number:12/214,555
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,366,600

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Teva Branded Pharm ZECUITY sumatriptan succinate SYSTEM;IONTOPHORESIS 202278-001 Jan 17, 2013 DISCN Yes No   Start Trial   Start Trial METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,366,600

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2008358026   Start Trial
Australia 2015224400   Start Trial
Canada 2727926   Start Trial
China 102065807   Start Trial
China 104027885   Start Trial
Eurasian Patent Organization 023339   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Dow
McKesson
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.